Skip to main content
We may receive compensation from affiliate partners for some links on this site. Read our full Disclosure here.

Thailand Princess Suddenly Collapses of Heart Attack While Running


On Wednesday, Thailand Princess Bajrakitiyabha, 44, collapsed during a canine training session in preparation for the Royal Thai Army event to run with dogs at the Working Dog Championship contest in Pak Chong district.

According to reports, she suffered a heart attack.

The local prognosis for Princess Bajrakitiyabha is “grim” and she is not expected to survive.

According to journalist Andrew MacGregor Marshall, the princess was taken to a nearby hospital, then taken by helicopter to Bangkok, where she is being treated.

He noted that the princess is being ‘artificially kept alive’ on an ECMO machine.

Although there hasn’t been an official announcement by the regime, some reports indicate that the princess, who is next in line to the throne, was pronounced dead by doctors.

The U.S. Embassy wrote:

The U.S. Embassy in Thailand extends its best wishes for a speedy and full recovery to Her Royal Highness Princess Bajrakitiyabha Narendiradebyavati Krom Luang Ratchasarinee Siripatchara Maha Watchara Ratchathida.

As Newspunch noted, Thailand’s controversial king has profited from the COVID-19 shots:

Princess Bajrakitiyabha’s father, the controversial King Vajiralongkorn, has been profiting from the Covid-19 vaccine roll-out in Thailand.

As the owner of the Thai pharmaceutical company Siam Bioscience, the king’s pockets have been lined to the tune of 4,650% profits since the company started producing AstraZeneca’s Covid-19 vaccine in 2021.

Via Reuters:

Thai drugmaker Siam Bioscience, owned by the country’s king, reported a near 50-fold increase in annual profit in 2021, when it began producing AstraZeneca Plc’s (AZN.L) COVID-19 vaccine, government data shows.

The company is part of King Maha Vajiralongkorn’s vast fortune, which includes land and property estimated at between $30 billion and $60 billion.

Founded in 2009 by the late King Bhumibol Adulyadej to produce biopharmaceuticals and improve public health, the company had since been loss-making and reported its first profit only in 2020 of 35.7 million baht ($995,000).

Its business improved sharply last year, as it began manufacturing vaccines for the first time.

Profit soared a whopping 4,650% to 1.69 billion baht and revenues increased by 1,500% to a record 4.9 billion baht, aided by its contract to manufacture 200 million doses of the Anglo-Swedish firm’s COVID-19 vaccine.

The deal came under fire from a prominent Thai opposition politician who questioned why the contract went to a company that was owned by the king and had never made vaccines before.


Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

Hey, Noah here!

Wondering where we went?

Read this and bookmark our new site!

See you over there!

Thanks for sharing!